♥ HF Guideline NavigatorESC 2026

7 › 7.5

7.5 Treatment

Pages 48–52 · open in PDF

Recommendations in this section

  • Class ILevel COxygen is recommended in patients with SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia.
  • Class ILevel CIntubation is recommended in patients with DHF and persistent and progressive respiratory failure despite oxygen administration or non-invasive ventilation to correct hypoxaemia.
  • Class IIaLevel B2Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO2 <90%) and started as soon as possible in order to decrease respiratory distress and reduce the risk of endotracheal intubation.
  • Class ILevel AIntravenous loop diuretics are recommended for all patients with DHF admitted with fluid overload to improve symptoms.
  • Class IIaLevel B1The addition of short-term intravenous acetazolamide or oral hydrochlorothiazide should be considered in patients with fluid overload previously treated with loop diuretics, to reduce congestion.
  • Class IIbLevel B1Urinary Na⁺-guided diuretic therapy may be considered during the first days of treatment of patients with DHF to improve natriuresis and diuresis.
  • Class ILevel B1In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion symptoms and reduce the risk of HFH.
  • Class IIbLevel CIntravenous vasodilators may be considered as initial therapy in patients with DHF and systolic blood pressure >110 mmHg to improve symptoms and reduce congestion.
  • Class IIbLevel CInotropic agents may be considered in patients with systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion.
  • Class IIbLevel CVasopressors, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ perfusion.
  • Class IIILevel CRoutine use of opiates is not recommended in patients with DHF unless severe/intractable pain or anxiety, due to risk of harm.
  • Class ILevel CA multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type) based on patient and HF characteristics.
  • Class IIaLevel B1Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with left ventricular systolic dysfunction and no risk of hypoxic brain injury in order to reduce the risk of death.
  • Class IIILevel B1Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of harm.
  • Class IIILevel B1IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect.
  • Class IIaLevel CTemporary MCS should be considered in patients with mechanical complications related to MI as a bridge to definitive treatment.
  • Class IIaLevel CTemporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB, BTC, or BTT.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 48 · PDF

7.5. Treatment 7.5.1. Oxygen therapy Oxygen therapy is recommended in patients with hypoxaemia [oxygen saturation (SpO2) <90% or partial pressure of oxygen (PaO2) <60 mmHg]. Studies, including RCTs, have demonstrated that indiscriminate oxygen administration in non-hypoxaemic patients may be harmful.499–501

Non-invasive ventilation is recommended in patients with APO or CS and respiratory failure to improve oxygenation and reduce the need for intubation as shown by multiple trials and meta analyses.502,503 However, the increase in intrathoracic pressure with non-invasive positive pressure ventilation decreases venous return and right and left ventricular preload. It may also decrease cardiac output and blood pressure and should therefore be used with caution in patients with reduced preload reserve and hypotension (i.e. decompensated right-sided HF). Endotracheal intubation is reserved for selected cases (see Recommendation Table 9).477

7.5.3. Diuretics (decongestion management) Intravenous loop diuretics remain the cornerstone of decongestion in DHF. In the DOSE-AHF trial, no difference in the primary efficacy outcome of patients’ symptom global assessment was shown with a high-dose regimen compared with a low-dose regimen of furosemide. There is no evidence indicating differential outcomes with i.v. bolus administration compared to continuous infusion or that one loop diuretic is superior to another.327,504 Patients naïve to diuretics usually respond well to 40 mg of i.v. furosemide or equivalent, whereas i.v. doses of two times the patient’s usual oral diuretic dose should be considered for patients who have been on loop diuretics as outpatients.505 Possible worsening kidney function should be evaluated in the context of diuretic response, because small and transient rises in serum creatinine during diuretic therapy are not associated with poor outcome if decongestion is achieved.506,507 Subsequent doses of loop diuretics during the initial days of hospitalization may be adjusted based on urinary sodium (uNa+) assessments, diuretic response, and the patient’s clinical status. A satisfactory diuretic response can be defined as a uNa+ content ≥70 mEq/L at 2 h or by a urine output ≥100 mL/h during the first 6 h (Figure 15). The PUSH-AHF trial showed that a strategy based on frequent clinical assessment, and uNa+-guided diuretic therapy led to higher natriuresis at 24 h vs standard of care.508 In the ENACT-HF open-label study, the uNa+-based approach also resulted in higher natriuresis and diuresis, as well as shorter hospital stay.509 No clinical trial has thus far showed benefit of uNa+-guided diuretic therapy on death or recurrent HFH. Intravenous diuretics should be continued until optimal decongestion is achieved; then, a switch to oral diuretics, if needed to maintain the volume status, is recommended. If there is an insufficient diuretic response, the loop diuretic i.v. dose can be doubled and/or a non-loop diuretic added. (Figure 15). Two recent RCTs examined the role of non-loop diuretics for enhanced decongestion in DHF. In the ADVOR trial, patients

were randomized to i.v. acetazolamide (500 mg) or placebo added to i.v. loop diuretics. Treatment with acetazolamide resulted in a greater incidence of successful decongestion, defined as the absence of signs of volume overload within 3 days.510 In the CLOROTIC trial, oral hydrochlorothiazide (dose adjusted for eGFR) was compared with placebo in patients receiving i.v. furosemide.511 The treatment with hydrochlorothiazide resulted in more pronounced weight loss at 72 h but did not impact patientreported dyspnoea. Treatment with hydrochlorothiazide was associated with greater 24 h diuresis but also more likely worsened kidney function and hypokalaemia, warranting caution. Importantly, the study was prematurely halted due to slow recruitment. Both ADVOR and CLOROTIC did not show benefit of non-loop diuretics on hard endpoints. The pharmacotherapy of different diuretics and a practical guidance for their use in DHF is reported in Supplementary data online, Table S13. In patients with DHF, fluid intake should be less than urine output and fluid restriction may be appropriate in patients with hyponatraemia, based on individual assessment. Similarly, sodium intake should remain less than natriuresis. Implementing SGLT2-I and neurohormonal blockade, including MRA, can contribute to more effective and sustainable decongestion.512–514 Thus, it is imperative to consider early implementation and optimization of FMT in parallel to decongestion (Figure 15).

7.5.4. Decongestion management in the ambulatory setting In ambulatory patients with chronic HF showing signs of worsening, both i.v. diuretic administration and intensification of oral diuretic therapy can be considered. A practical guide for the outpatient management of WHF has been published, covering both ambulatory i.v. diuretics administered in a day-hospital setting and ‘hospital-at-home’ care models, including telehealth-enabled approaches.515–517 Diuretic sessions usually consist of a 3–6 h i.v. diuretic infusion with dosing based on the patient’s existing oral diuretic regimen. Close monitoring of kidney function, electrolyte levels, and treatment response, including measurements of urine output, uNa+, signs of clinical decongestion, biomarkers, and/or ultrasound findings, is essential.444,515,518 The new formulations of diuretics (e.g. subcutaneous) might be particularly useful for home treatment.519–521 Intensification of oral diuretic therapy may include: (i) initiating a loop diuretic in previously untreated individuals; (ii) increasing the total daily dose of a loop diuretic; or (iii) temporarily adding a diuretic with a different mechanism of action. Thiazide-like diuretics—particularly oral metolazone (2.5–5 mg)—can be used in patients with advanced HF who exhibit diuretic resistance, as part of a sequential nephron blockade approach, or in those with an eGFR <30 mL/min/1.73 m2. This strategy requires careful monitoring of eGFR and electrolytes. Patients with WHF that progresses to advanced HF are a key population for either outpatient i.v. diuretic treatment, whether in a day hospital or ‘hospital-at-home’ setting, or oral thiazidelike diuretics. Indeed, these patients often experience frequent hospitalizations and spend a substantial amount of time in hospital (‘frequent flyers’). Such patients require prompt evaluation for advanced HF treatments (see Section 8).

7.5.2. Ventilation support

Page 49 · PDF

Start i.v. loop diuretic (40 mg furosemide in diuretic naive or double daily oral dose in chronic users)a

Repeat the diuretic regime every 12 h until complete decongestionb

Double the dose of loop diuretic OR Consider adding i.v. acetazolamide or eGFR based hydrochlorothiazidec (in case of chronic loop diuretic use)

Spot uNa+ at 2–6 h ≥70 mmol/L OR Urine output at 6h ≥100 mL/h

Progressive escalation of loop diuretics up to the maximum i.v. dosed AND Consider adding other non-loop diuretics

Consider ultrafiltration in case of unsuccessful decongestion despite maximal diuretic therapy

FMT initiation/uptitration Check frequently for hypotension/hypoperfusion. Check serum creatinine and electrolytese at least every 24 h

Figure 15 Management of decongestion. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FMT, foundational

medical therapy; i.v., intravenous; K+, potassium; MRA, mineralocorticoid receptor antagonist; uNa+, urinary sodium. aHigher initial i.v. dose in case of CKD. bAfter 24 h of treatment, total diuresis should be taken into consideration. If diuresis remains <3 l and congestion persists, further diuretic escalation should be considered during the second day of treatment. cAcetazolamide (500 mg i.v. once daily) or hydrochlorothiazide (if eGFR >50 mL/min/1.73 m2: 25 mg daily; eGFR 20–50 mL/min/1.73 m2: 50 mg daily; and eGFR <20 mL/min/ 1.73 m2: 100 mg daily). Acetazolamide might be preferable in more advanced CKD. dThe highest daily dose for i.v. loop diuretics is generally considered furosemide 600 mg, although up to 1000 mg may be considered in patients with severely impaired kidney function. e Consider MRA and K+ supplements in case of hypokalaemia.

Spot uNa+ at 2 h ≥70 mmol/L OR Urine output at 6h ≥100 mL/h

Page 50 · PDF

50 7.5.5. Sodium–glucose co-transporter 2 inhibitors

use of norepinephrine as first choice, compared with dopamine or epinephrine. Dopamine vs norepinephrine was associated with significantly higher rate of arrhythmic events in an RCT including patients with unspecified shock.538 In the CS subgroup, a mortality benefit was observed with norepinephrine, although without a significant P-value for interaction. Comparing epinephrine and norepinephrine showed similar effects on cardiac index in a small trial of infarct-related CS.539 However, this trial was stopped prematurely due to a higher incidence of refractory shock with epinephrine. Vasopressin has not been studied in CS so far. The target mean blood pressure is not well defined in CS. For more details, see Supplementary data online, Table S16.

7.5.10. Opiates 7.5.6. Ultrafiltration Given the available data, the role of ultrafiltration in managing DHF remains uncertain, but it may be considered in selected patients who are responding insufficiently to diuretic escalation.527,528

7.5.7. Vasodilators Intravenous vasodilators (i.v. nitroglycerine or nitroprusside) may be effective in patients with DHF, particularly in those with predominant vasoconstriction and volume redistribution. For example, in APO, where increased cardiac filling pressures and elevated systemic blood pressures occur in the absence of, or with minimal, systemic fluid accumulation, vasodilators can reduce pulmonary congestion (Supplementary data online, Section S4.3 and Table S14).529 Importantly, close monitoring of blood pressure is recommended during drug administration, as hypotension related to vasodilatation may be harmful.529,530 None of the large-scale RCTs have shown a clear clinical benefit of vasodilatation on hard endpoints.531–533 A meta-analysis of available RCTs has demonstrated that using vasodilators was associated with a lower risk of tracheal intubation in DHF with no effect on death or length of hospital stay.534

7.5.8. Inotropes/inodilators Inotropic agents may be considered in patients with DHF, systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion. Due to risks of arrhythmias and myocardial ischaemia, their use is not routinely recommended in patients with DHF and should be cautious.535 A Cochrane analysis found insufficient evidence to establish mortality benefits of any inotrope in patients with CS or low cardiac output.536 An RCT found no difference between milrinone and dobutamine.537 For levosimendan, no relevant RCTs in CS are available. Based on the mode of action, levosimendan or phosphodiesterase-III inhibitors may be preferred over dobutamine for patients on beta-blockers. For more details on the specific inotropic agents, see Supplementary data online, Tables S15 and S16.

7.5.9. Vasopressors Vasopressors may be considered in patients with hypotension and DHF. Some studies, although with limitations, support the

Routine use of opiates is not recommended in patients with DHF; Their use should be limited to carefully selected patients with severe anxiety or distress refractory to other treatments and must be approached with caution due to the risk of respiratory failure.

Recommendation Table 9 — Recommendations for the immediate and intermediate treatment of decompensated heart failure (see Evidence Tables 59–67) Recommendations

Oxygen and ventilatory support Oxygen is recommended in patients with SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia. Intubation is recommended in patients with DHF and persistent and progressive respiratory failure despite oxygen administration or non-invasive ventilation to correct hypoxaemiac. Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO2 <90%) and started as soon as possible in order to decrease respiratory distress and reduce the risk of endotracheal intubation.540 Diuretics Intravenous loop diuretics are recommended for all patients with DHF admitted with fluid overload to improve symptomsd. The addition of short-term intravenous acetazolamide or oral hydrochlorothiazide should be considered in patients with fluid overload previously treated with loop diuretics, to reduce congestion.510,511 Urinary Na+-guided diuretic therapy may be considered during the first days of treatment of patients with DHF to improve natriuresis and diuresis.508 Continued

Several trials and meta-analyses have confirmed the safety and clinical benefit of in-hospital initiation of an SGLT2-I.492,522–525 The EMPULSE trial demonstrated that in-hospital initiation of 10 mg empagliflozin resulted in significantly higher chances of clinical benefit, at 90 days.492 In the SOLOIST-WHF trial, initiation of sotagliflozin in hospital or within 3 days of discharge was safe and effective in patients with HF and diabetes.326 Initiation of SGLT2-Is in HF has been shown to be associated with lower diuretic demand and facilitated decongestion even though the long-term ‘diuretic effect’ of SGLT2-Is is unknown.514,522–524,526 Thus, early initiation of SGLT2-Is in DHF is recommended both as part of FMT (i.e. prognostic implications) and as a tool to enable optimal decongestion (Figure 15).

Page 51 · PDF

suggests that temporary MCS are beneficial in highly selected patients with ST-elevation MI complicated by CS who do not have hypoxic brain injury, although rates of severe complications remain high.546

SGLT2-I In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion

symptoms and reduce the risk of HFH.492,522,525,541

7.5.11.1. Microaxial flow pumps

Vasodilators initial therapy in patients with DHF and systolic blood pressure >110 mmHg to improve

symptoms and reduce congestion.534 Inotropic agents Inotropic agents may be considered in patients with systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion. Vasopressors Vasopressors, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ Opiates Routine use of opiates is not recommended in patients with DHF unless severe/intractable pain or anxiety, due to risk of harm.542

DHF, decompensated heart failure; HFH, heart failure hospitalization; NIV, non-invasive ventilation; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of oxygen; QoL, quality of life; SGLT2-I, sodium–glucose co-transporter 2 inhibitor; SpO2, oxygen saturation. a Class of recommendation. b Level of evidence. c Criteria for endotracheal intubation in DHF: cardiac or respiratory arrest, progressive worsening of altered mental status, progressive worsening of respiratory failure with hypoxaemia (PaO2 <60 mmHg, PaCO2 >50 mmHg and pH <7.35) despite NIV or intolerance to NIV, persistent haemodynamic instability, need for airway protection.477 d This recommendation is considered by the Task Force to have level of evidence A due to clear clinical benefit. Treatment of DHF with loop diuretics has been widely accepted as effective and therefore no adequately powered randomized clinical trial has ever been conducted or is likely to be conducted for ethical reasons.

7.5.11. Temporary mechanical circulatory support Temporary MCS should be considered as an option for stabilizing haemodynamics and enhancing end-organ perfusion in highly selected patients.434,474,543,544 Different percutaneous devices operate through distinct mechanisms, delivering diverse haemodynamic support levels, each associated with specific potential benefits but also possible complications. In addition to single use, multiple combinations are feasible, addressing specific needs for LV unloading or combined left and right ventricular support. Decisions on the modality and type of temporary MCS should be guided by a multidisciplinary Shock Team including a cardiologist specialized in HF, a cardiothoracic surgeon, an interventional cardiologist, and an intensive care specialist, working at an experienced advanced HF centre (i.e. highvolume for temporary MCS).488,545 A recent meta-analysis

7.5.11.2. Venoarterial extracorporeal life support Extracorporeal life support (ECLS) can deliver support of up to 6 l/min and provide full respiratory and circulatory support. In the ECLS-SHOCK trial involving patients with severe infarct-related CS, early routine ECLS use showed no significant difference in 30-day all-cause death (relative risk 0.98; 95% CI 0.80–1.19).552 These data are in line with an individual patient data meta-analysis of ECLS RCTs in patients with infarct-related CS in which no mortality benefit was observed but more complications with ECLS were seen.553 Importantly, ECLS may harm the heart itself owing to the afterload increase by generation of retrograde blood flow. Active unloading with microaxial flow pumps or intra-aortic balloon pump (IABP) aims to mitigate these adverse effects. A recent RCT comparing routine LV unloading by a transseptal left atrial cannula vs ECLS alone showed no effect on death.554 RCTs investigating the efficacy of ECLS in non-ischaemic CS have yet to be performed.

7.5.11.3. Intra-aortic balloon pump Routine use of IABP is not recommended in unselected patients with CS. In the IABP shock trial, 40 patients with post-MI CS were randomised to IABP treatment or standard of care. Treatment with IABP did not significantly augment cardiac output or any other haemodynamic variable as compared to control.555 In a large-scale RCT in infarct-related CS, routine use of IABP did not show a survival benefit compared with medical therapy at 30-day and longer follow-up.556–558 Also, in advanced HF CS, IABP had no survival benefit as compared to standard of care.559,560 The decision to use an IABP should therefore be highly individualized, based on patient-specific factors and the availability of alternative therapies.559,561–563

Intravenous vasodilators may be considered as

Microaxial percutaneous flow pumps provide support of up to 4 l/min. Newer devices with 5.5 l/min requiring surgical insertion offer complete LV support. Until recently, the percutaneous device had been investigated in a few RCTs on infarct-related CS and in large-scale propensity-matched studies encompassing more than 100 000 patients and consistently showed no survival benefit with higher complication rates such as major bleeding and limb ischaemia.547,548 In the DanGer Shock trial, including 360 highly selected patients with ST-elevation MI and CS, treatment with microaxial flow pump vs standard of care was associated with lower 180-day death (HR 0.74; 95% CI 0.55–0.99; P = .04), which persisted up to 10-year follow-up.549,550 This trial also showed an increased incidence of bleeding and limb ischaemia compared with controls. Despite the mortality benefit observed in this trial, multiple open questions remain.548,551 Utilization of microaxial flow pumps should be considered in highly selected patients with CS caused by ST-elevation MI, who do not have risk of hypoxic brain injury. Routine use of microaxial flow pumps in CS is not recommended. RCTs on the efficacy of microaxial flow pumps in non-infarct-related CS have yet to be conducted.546

Page 52 · PDF

Recommendation Table 10 — Recommendations for the use of temporary mechanical circulatory support in patients with cardiogenic shock (see Evidence Tables 68 and 69)

A multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type)

based on patient and HF characteristics.564,565 Cardiogenic shock caused by acute MI Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with left ventricular systolic dysfunction and no

risk of hypoxic brain injuryc in order to reduce the risk of death.546,549,550 Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of

All the following criteria must be present despite FMT, AMT, and GDIT: 1. Severe and persistent symptoms of HF (NYHA class III or IV). III

2. Severe cardiac dysfunction defined by at least one of the

• LVEF ≤30% • Isolated RV failure (e.g. ARVC)

IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect.557,560

• Non-operable severe valve abnormalities • Non-operable severe congenital abnormalities • Persistently high (or increasing) BNP or NT-proBNP values and

MI-related mechanical complications Temporary MCSd should be considered in patients with mechanical complications related

Criteria for definition of advanced heart failure

severe LV diastolic dysfunction or structural abnormalities (i.e. IIa

HFpEF,a hypertrophic or restrictive cardiomyopathies).

3. Episodes of pulmonary or systemic congestion requiring high-dose

Advanced HF cardiogenic shock

i.v. diuretics (or diuretic combinations) or malignant arrhythmias causing ≥2 unplanned visits or hospitalizations in the last 12 months,

Temporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB,

BTC, or BTT. BTB, bridge to bridge; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; HF, heart failure; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; MI, myocardial infarction; VA-ECLS, venoarterial extracorporeal life support. a Class of recommendation. b Level of evidence. c No risk of hypoxic brain injury was defined as: (i) no out-of-hospital cardiac arrest with persistent Glasgow coma scale <8 after return of spontaneous circulation549; and (ii) no resuscitation or resuscitation lasting <10 min.546 d The choice of passive IABP or active percutaneous MCS should be based on the severity of cardiogenic shock as assessed by the Shock Team. e In case of large ventricular septal defect, temporary MCS should be used with caution due to the potential increase of left-to-right interventricular shunt (VA-ECLS) or shunt inversion (microaxial flow pump). In case of ventricular free-wall rupture, temporary MCS should be avoided; however, VA-ECLS can be considered to allow emergent cardiac surgery in patients presenting with profound cardiogenic shock and/or cardiac arrest if no sign of irreversible brain injury is present.

7.5.12. Thromboembolism prophylaxis Although patients with DHF are recognized as being at increased thromboembolic risk, no RCT has compared anticoagulation vs placebo in a DHF population, thus no definitive recommendation can be made.566–570 However, in case of immobilization or other risk factors, thromboembolic prophylaxis is generally indicated.

to MI as a bridge to definitive treatment.

or ≥1 episode of low output requiring inotropes or vasoactive drugs. 4. Severe impairment of exercise capacity with inability to exercise, or low 6-min walk test distance (<300 m), or pVO2 <12–14 mL/kg/ min,b or <50% predicted value, estimated to be of cardiac origin. AMT, additional medical therapy; ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, B-type natriuretic peptide; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; i.v., intravenous; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; pVO2, peak oxygen consumption; RV, right ventricular. a See Table 10. b The cut-off 12 mL/kg/min refers to patients on beta-blocker.

A severely reduced LVEF is common but not required for a diagnosis of advanced HF, as it may develop in patients with HFpEF or other structural abnormalities. Early risk stratification and timely referral to an advanced HF centre are crucial to improve outcomes (Figure 16).574,575 Systematic assessment for advanced HF using the ‘Rule of three’ or ‘I NEED HELP’ criteria is essential for timely referral to an advanced HF centre576–578 (Figure 16 and Table 15). Cardiopulmonary exercise testing and right heart catheterization (RHC) are key tools for risk stratification and eligibility assessment.579–582 Women and sociocultural minority groups are less likely to receive MCS and heart transplantation for reasons not explained by medical factors or social determinants of health and deserve extra attention for timely referral and patient communication.583–585

Many patients with HF progress into a phase of advanced HF (stage D), characterized by persistent severe symptoms and objective measures of cardiogenic impairment despite optimal therapy. In the Framingham population, 5.1%–7.7% of patients with HF had advanced HF.571 Prognosis in medically treated patients with advanced HF remains poor with 1-year mortality >40%.572,573 Criteria for definition are reported in Table 14.572

8.1. Epidemiology, definition, prognosis, and referral